Compare IAC & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IAC | HCM |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1811 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 2020 | N/A |
| Metric | IAC | HCM |
|---|---|---|
| Price | $44.31 | $14.09 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 13 | 1 |
| Target Price | ★ $46.58 | $13.75 |
| AVG Volume (30 Days) | ★ 946.9K | 37.0K |
| Earning Date | 05-04-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,365,235,000.00 | N/A |
| Revenue This Year | N/A | $20.60 |
| Revenue Next Year | $0.48 | $15.62 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.56 | $13.06 |
| 52 Week High | $45.82 | $19.50 |
| Indicator | IAC | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 70.85 | 38.24 |
| Support Level | $38.29 | $13.08 |
| Resistance Level | N/A | $15.59 |
| Average True Range (ATR) | 1.05 | 0.45 |
| MACD | 0.20 | -0.17 |
| Stochastic Oscillator | 76.05 | 12.75 |
IAC Inc is comprised of businesses including Angi Inc, Dotdash Meredith and Care.com, among many others ranging from early stage to established businesses. Its Dotdash Meredith segment consists of its Digital and Print businesses. Angi segment offers repairing and remodeling homes to cleaning and landscaping services. Care.com segment is a online destination for families to connect with caregivers for their children, aging parents, pets and homes and for caregivers to connect with families seeking care services. Search segment consists of a collection of websites providing general search services and information, and a Desktop business, which includes business-to-business partnership operations.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.